The effect of hormone replacement therapy on CYP3A activity

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 4, 2000, Pages 412-417

  Gorski, J Christopher ^a   Wang, Zaiqi ^a   Haehner Daniels, Barbara D ^a   Wrighton, Steven A ^a   Hall, Stephen D ^a,b  

^a WISHARD MEMORIAL HOSPITAL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; ESTROGEN; MIDAZOLAM;

AGED; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; ENZYME ACTIVITY; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; INTESTINE WALL; MENOPAUSE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-ANXIETY AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; INFUSIONS, INTRAVENOUS; MIDAZOLAM; OXIDOREDUCTASES, N-DEMETHYLATING; PROGESTERONE;

EID: 0033752245     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.110560     Document Type: Article

References (34)

1. Oral contraceptive drug interactions: Important considerations
2. Drug interactions with oral contraceptives
3. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy
4. Sex, age and alfentanil pharmacokinetics
5. The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics
6. Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens
7. Identifica tion of the pharmacogenetic determinants of alfentanil metabolism: Cytochrome P-450 3A4: An explanation of the variable elimination clearance
8. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man
9. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone
10. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole
11. The human hepatic cytochromes P450 involved in drug metabolism
12. In vitro and in vivo drug interactions involving human CYP3A
13. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents
14. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin
15. Dose of midazolam should be reduced during diltiazem and verapamil treatments
16. A potentially hazardous interaction between erythromycin and midazolam
17. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole
18. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene
19. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P450
20. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily
21. Clinical pharmacokinetics: Concepts and applications
22. The effect of age upon liver volume and apparent liver blood flow in healthy man
23. Excretion and metabolism of 14C-midazolam in humans following oral dosing
24. Effect of age, gender, and obesity on midazolam kinetics
25. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4
26. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1 alpha,25-dihydroxyvitamin D3
27. Use of midazolam as a human cytochrome P450 3A probe: I - In vitro-in vivo correlations in liver transplant patients
28. Differentiation of absorption and first pass gut and hepatic metabolism in humans: Studies with cyclosporine
29. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin
30. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism
31. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction
32. Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions, and interindividual variability
33. Ethynylestradiol-mediated induction of hepatic CYP3A9 in female rats: Implication for cyclosporine metabolism
34. Cyclosporin pharmacokinetics in the elderly